Porton Pharma Solutions
Porton Pharma Solutions, headquartered in China, is a leading player in the pharmaceutical and biotechnology industry, specialising in contract development and manufacturing services (CDMO). Founded in 2003, the company has established a strong presence in key operational regions, including Asia, Europe, and North America. Porton Pharma is renowned for its comprehensive range of services, including active pharmaceutical ingredient (API) production, formulation development, and clinical trial material supply. What sets Porton apart is its commitment to quality and innovation, ensuring that clients receive tailored solutions that meet stringent regulatory standards. With a robust market position, Porton Pharma Solutions has achieved significant milestones, including successful collaborations with global pharmaceutical companies, solidifying its reputation as a trusted partner in the drug development process.
DitchCarbon Score
How does Porton Pharma Solutions's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Porton Pharma Solutions's score of 35 is higher than 91% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Porton Pharma Solutions's reported carbon emissions
In 2023, Porton Pharma Solutions reported total greenhouse gas emissions of approximately 109,692,520 kg CO2e, comprising about 19,859,890 kg CO2e from Scope 1 and about 89,832,630 kg CO2e from Scope 2 emissions. This represents a slight decrease from 2022, where total emissions were about 105,616,610 kg CO2e, with Scope 1 at approximately 20,121,610 kg CO2e and Scope 2 at about 85,495,000 kg CO2e. Porton Pharma Solutions has set ambitious climate commitments, aiming to reduce absolute Scope 1 and 2 emissions by 42% by 2030, using 2023 as the baseline year. Additionally, the company plans to cut Scope 3 emissions, which include emissions from purchased goods and services, upstream transportation, and waste generated in operations, by 25% within the same timeframe. These targets align with the Science Based Targets initiative (SBTi) and reflect Porton Pharma's commitment to addressing climate change within the pharmaceutical sector. The company is actively working towards these goals to enhance sustainability and reduce its carbon footprint.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|
| Scope 1 | 26,761,250 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 67,599,610 | 00,000,000 | 00,000,000 | 000,000,000 |
| Scope 3 | - | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Porton Pharma Solutions is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
